Open

Endometrial Cancer Study

In this study, we want to learn if we can lower the chances of your endometrial cancer growing or spreading by adding a drug to treatment with a hormonal drug.

Age & Gender

18 years ~ 99 years
Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

If you decide to take part in this study, you will get megestrol acetate (MA) and ipatasertib until your disease gets worse or if your side effects become too severe.

Incentives

Study Medication

Total length of participation:
Until disease progression

Looking for Specific Volunteers

Able to participate:

You have Endometrioid Endometrial Cancer
You haven't had hormone therapy in the last 6 months
You are able to swallow and retain oral medications

Not eligible if:

You have had treatment with an AKT inhibitor
You have diabetes that is not under control
You have a history of or presence of an abnormal ECG
You have active infection requiring antibiotics

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Olivia Lara
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Uterine (endometrial))
Women's Health

IRB Number

23-1374

ClinicalTrials.gov

NCT05538897

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.